Analysis of protein isoforms: Can we do it better?

Proteomics

Volumn 12, Issue 19-20, 2012, Pages 2937-2948

  Stastna, Miroslava ^a,b   Van Eyk, Jennifer E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSTITUTE OF ANALYTICAL CHEMISTRY   (Czech Republic)

Author keywords

Accurate and complete identification quantification; Intact protein analysis; Novel proteomic approaches; Protein isoforms splice variants; Technology

Indexed keywords

B CELL ACTIVATING FACTOR; BIOLOGICAL MARKER; COLONY STIMULATING FACTOR 1; CYTOKINE; ENIGMA HOMOLOG SPLICE VARIANT 1; ENIGMA HOMOLOG SPLICE VARIANT 4; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FIBRONECTIN; INTERFERON RECEPTOR; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; NEU DIFFERENTIATION FACTOR; OSTEOPONTIN; PEPTIDE; PLATELET DERIVED GROWTH FACTOR; PROTEIN; PROTEIN P53; SOMATOMEDIN B; SOMATOMEDIN C; T CELL FACTOR 7 LIKE 2; THROMBOPOIETIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP1; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; UNCLASSIFIED DRUG; VASCULOTROPIN;

ACCURACY; AMINO ACID SEQUENCE; ANALYTIC METHOD; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; AUTOIMMUNE DISEASE; BREAST CANCER; CANCER THERAPY; ELECTROSPRAY MASS SPECTROMETRY; EMBRYONIC STEM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXERCISE; FIBROSIS; HEART INFARCTION; HUMAN; HYDROPHOBIC INTERACTION CHROMATOGRAPHY; ION EXCHANGE CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; LUNG NON SMALL CELL CANCER; MULTIPLE SCLEROSIS; PEPTIDE ANALYSIS; PLURIPOTENT STEM CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEOMICS; QUANTITATIVE ANALYSIS; REVIEW; SEPARATION TECHNIQUE; SEQUENCE HOMOLOGY; TECHNOLOGY; TREATMENT RESPONSE; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; CHROMATOGRAPHY, LIQUID; HUMANS; MASS SPECTROMETRY; MOLECULAR SEQUENCE DATA; PROTEIN ISOFORMS; PROTEOMICS; SEQUENCE ALIGNMENT;

EID: 84867800367     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201200161     Document Type: Review

References (109)

1. Perrin, B. J., Ervasti, J. M., The actin gene family: function follows isoforms. Cytoskeleton 2010, 67, 630-634.
2. Grabowski, P. J., Black, D. L., Alternative RNA splicing in the nervous system. Prog. Neurobiol. 2001, 65, 289-308.
3. Black, D. L., Mechanisms of alternative pre-messenger RNA splicing. Annu. Rev. Biochem. 2003, 72, 291-336.
4. Blencowe, B. J., Alternative splicing: new insights from global analyses. Cell 2006, 126, 37-47.
5. Bracco, L., Throo, E., Cochet, O., Einstein, R. et al., Methods and platforms for the quantification of splice variants' expression. Prog. Mol. Subcell Biol. 2006, 44, 1-25.
6. Schindler, S., Heiner, M., Platzer, M., Szafranski, K., Comparison of methods for quantification of subtle splice variants. Electrophoresis 2009, 30, 3674-3681.
7. Howard, B. E., Heber, S., Towards reliable isoform quantification using RNA-SEQ data. BMC Bioinformatics 2010, 11(Suppl 3), S6.
8. Mironov, A. A., Fickett, J. W., Gelfand, M. S., Frequent alternative splicing of human genes. Genome Res. 1999, 9, 1288-1293.
9. Pan, Q., Shai, O., Lee, L. J., Frey, B. J. et al., Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat. Genet. 2008, 40, 1413-1415.
10. Sorek, R., Shamir, R., Ast, G., How prevalent is functional alternative splicing in the human genome? Trends Genet. 2004, 20, 68-71.
11. Lareau, L. F., Green, R. E., Bhatnagar, R. S., Brenner, S. E., The evolving roles of alternative splicing. Curr. Opin. Struct. Biol. 2004, 14, 273-282.
12. Baralle, D., Baralle, M., Splicing in action: assessing disease causing sequence changes. J. Med. Genet. 2005, 42, 737-748.
13. Matlin, A. J., Clark, F., Smith, C. W., Understanding alternative splicing: towards a cellular code. Nat. Rev. Mol. Cell Biol. 2005, 6, 386-398.
14. Brinkman, B. M., Splice variants as cancer biomarkers. Clin. Biochem. 2004, 37, 584-594.
15. Yi, Q., Tang, L., Alternative spliced variants as biomarkers of colorectal cancer. Curr. Drug Metab. 2011, 12, 966-974.
16. Omenn, G. S., Yocum, A. K., Menon, R., Alternative splice variants, a new class of protein cancer biomarker candidates: findings in pancreatic cancer and breast cancer with systems biology implications. Dis. Markers 2010, 28, 241-251.
17. Hilmi, C., Guyot, M., Pages, G., VEGF splice variants: possible role of anti-angiogenesis therapy. J. Nucleic Acids 2012, 2012, 162692.
18. Blair, C. A., Zi, X., Potential molecular targeting of splice variants for cancer treatment. Indian J. Exp. Biol. 2011, 49, 836-839.
19. Miranda, E. R., De Marco, L., Soares, M. M., Splicing variants impact in thyroid normal physiology and pathological conditions. Arq. Bras Endocrinol. Metabol. 2009, 53, 709-715.
20. Srebrow, A., Kornblihtt, A. R., The connection between splicing and cancer. J. Cell Sci. 2006, 119, 2635-2641.
21. Pio, R., Montuenga, L. M., Alternative splicing in lung cancer. J. Thorac. Oncol. 2009, 4, 674-678.
22. Hayes, N. V., Gullick, W. J., The neuregulin family of genes and their multiple splice variants in breast cancer. J. Mammary Gland Biol. Neoplasia 2008, 13, 205-214.
23. Gilli, F., Role of differential expression of interferon receptor isoforms on the response of multiple sclerosis patients to therapy with interferon beta. J. Interferon Cytokine Res. 2010, 30, 733-741.
24. Yamazaki, T., Walchli, S., Fujita, T., Ryser, S. et al., Splice variants of enigma homolog, differentially expressed during heart development, promote or prevent hypertrophy. Cardiovasc. Res. 2010, 86, 374-382.
25. Youinou, P., Pers, J. O., The late news on baff in autoimmune diseases. Autoimmun. Rev. 2010, 9, 804-806.
26. Hansson, O., Zhou, Y., Renstrom, E., Osmark, P., Molecular function of TCF7L2: consequences of TCF7L2 splicing for molecular function and risk for type 2 diabetes. Curr. Diab. Rep. 2010, 10, 444-451.
27. Gabut, M., Samavarchi-Tehrani, P., Wang, X., Slobodeniuc, V. et al., An alternative splicing switch regulates embryonic stem cell pluripotency and reprogramming. Cell 2011, 147, 132-146.
28. Kelleher, N. L., Top-down proteomics. Anal. Chem. 2004, 76, 197A-203A.
29. Bogdanov, B., Smith, R. D., Proteomics by FTICR mass spectrometry: top down and bottom up. Mass Spectrom. Rev. 2005, 24, 168-200.
30. Hung, C. W., Tholey, A., Tandem mass tag protein labeling for top-down identification and quantification. Anal. Chem. 2012, 84, 161-170.
31. Lee, J. L., Chen, H., Liu, T., Berkman, C. E. et al., High resolution time-of-flight mass analysis of the entire range of intact singly-charged proteins. Anal. Chem. 2011, 83, 9406-9412.
32. Tipton, J. D., Tran, J. C., Catherman, A. D., Ahlf, D. R. et al., Analysis of intact protein isoforms by mass spectrometry. J. Biol. Chem. 2011, 286, 25451-25458.
33. Garcia, B. A., What does the future hold for top down mass spectrometry? J. Am. Soc. Mass Spectrom. 2010, 21, 193-202.
34. Siuti, N., Kelleher, N. L., Decoding protein modifications using top-down mass spectrometry. Nat. Methods 2007, 4, 817-821.
35. Pesavento, J. J., Mizzen, C. A., Kelleher, N. L., Quantitative analysis of modified proteins and their positional isomers by tandem mass spectrometry: human histone H4. Anal. Chem. 2006, 78, 4271-4280.
36. Roth, M. J., Forbes, A. J., Boyne, M. T. 2nd, Kim, Y. B. et al., Precise and parallel characterization of coding polymorphisms, alternative splicing, and modifications in human proteins by mass spectrometry. Mol. Cell Proteomics 2005, 4, 1002-1008.
37. Tran, J. C., Zamdborg, L., Ahlf, D. R., Lee, J. E. et al., Mapping intact protein isoforms in discovery mode using top-down proteomics. Nature 2011, 480, 254-258.
38. Wang, H., Hanash, S., Intact-protein based sample preparation strategies for proteome analysis in combination with mass spectrometry. Mass Spectrom. Rev. 2005, 24, 413-426.
39. Stastna, M., Zhang, P., Murphy, A., Van Eyk, J. E., in: Hill, J. A., Olson, E. N. (Eds.), Cardiovascular Proteomics: Assessment of Protein Post-Translational Modifications, Chapter 19, Academic Press, London 2012, pp. 261-271.
40. McLafferty, F. W., Breuker, K., Jin, M., Han, X. et al., Top-down MS, a powerful complement to the high capabilities of proteolysis proteomics. FEBS J. 2007, 274, 6256-6268.
41. Chalmers, M. J., Mackay, C. L., Hendrickson, C. L., Wittke, S. et al., Combined top-down and bottom-up mass spectrometric approach to characterization of biomarkers for renal disease. Anal. Chem. 2005, 77, 7163-7171.
42. Millea, K. M., Krull, I. S., Cohen, S. A., Gebler, J. C. et al., Integration of multidimensional chromatographic protein separations with a combined "top-down" and "bottom-up" proteomic strategy. J. Proteome Res. 2006, 5, 135-146.
43. Durbin, K. R., Tran, J. C., Zamdborg, L., Sweet, S. M. et al., Intact mass detection, interpretation, and visualization to automate top-down proteomics on a large scale. Proteomics 2010, 10, 3589-3597.
44. Wang, H., Hanash, S., Intact-protein analysis system for discovery of serum-based disease biomarkers. Methods Mol. Biol. 2011, 728, 69-85.
45. Doucette, A. A., Tran, J. C., Wall, M. J., Fitzsimmons, S., Intact proteome fractionation strategies compatible with mass spectrometry. Expert Rev. Proteomics 2011, 8, 787-800.
46. Capriotti, A. L., Cavaliere, C., Foglia, P., Samperi, R. et al., Intact protein separation by chromatographic and/or electrophoretic techniques for top-down proteomics. J. Chromatogr. A 2011, 1218, 8760-8776.
47. Staub, A., Guillarme, D., Schappler, J., Veuthey, J. L. et al., Intact protein analysis in the biopharmaceutical field. J. PharmBiomed. Anal. 2011, 55, 810-822.
48. Staub, A., Zurlino, D., Rudaz, S., Veuthey, J. L. et al., Analysis of peptides and proteins using sub-2 μm fully porous and sub-3 μm shell particles. J. Chromatogr. A 2011, 1218, 8903-8914.
49. Hong, G., Gao, M., Yan, G., Guan, X. et al., Optimization of two-dimensional high performance liquid chromatographic columns for highly efficient separation of intact proteins. Se. Pu. 2010, 28, 158-162.
50. Yu, W., Li, Y., Deng, C., Zhang, X., Comprehensive two-dimensional separation in coupling of reversed-phase chromatography with capillary isoelectric focusing followed by MALDI-MS identification using on-target digestion for intact protein analysis. Electrophoresis 2006, 27, 2100-2110.
51. Wang, Y., Balgley, B. M., Rudnick, P. A., Lee, C. S., Effects of chromatography conditions on intact protein separations for top-down proteomics. J. Chromatogr A. 2005, 1073, 35-41.
52. Roth, M. J., Plymire, D. A., Chang, A. N., Kim, J. et al., Sensitive and reproducible intact mass analysis of complex protein mixture with superficially porous capillary reversed-phase liquid chromatography mass spectrometry. Anal. Chem. 2011, 83, 9586-9592.
53. Strancar, A., Podgornik, A., Barut, M., Necina, R., Short monolithic columns as stationary phases for biochromatography. Adv. Biochem. Eng. Biotechnol. 2002, 76, 49-85.
54. Xie, S., Allington, R. W., Frechet, J. M., Svec, F., Porous polymer monoliths: an alternative to classical beads. Adv. Biochem. Eng. Biotechnol. 2002, 76, 87-125.
55. Iwasaki, M., Sugiyama, N., Tanaka, N., Ishihama, Y., Human proteome analysis by using reversed phase monolithic silica capillary columns with enhanced sensitivity. J. Chromatogr. A 2012, 1228, 292-297.
56. Liu, J., Ren, L., Liu, Y., Li, H. et al., Weak anion exchange chromatographic profiling of glycoprotein isoforms on a polymer monolithic capillary. J Chromatogr A 2012, 1218, 276-282.
57. Eeltink, S., Svec, F., Recent advances in the control of morphology and surface chemistry of porous polymer-based monolithic stationary phases and their application in CEC. Electrophoresis 2007, 28, 137-147.
58. Guan, X., Yan, G., Gao, M., Hong, G., Intact-protein trapping columns for proteomic analysis in capillary high-performance liquid chromatography. J. Chromatogr. A 2010, 1217, 6875-6881.
59. Fausnaugh, J. L., Pfankoch, E., Gupta, S., Regnier, F. E., High-performance hydrophobic interaction chromatography of proteins. Anal. Biochem. 1984, 137, 464-472.
60. Goheen, S. C., Engelhorn, S. C., Hydrophobic interaction high-performance liquid chromatography of proteins. J. Chromatogr. 1984, 317, 55-65.
61. Cummins, P. M., O'Connor, B. F., Hydrophobic interaction chromatography. Methods Mol. Biol. 2011, 681, 431-437.
62. Fausnaugh, J. L., Kennedy, L. A., Regnier, F. E., Comparison of hydrophobic-interaction and reversed-phase chromatography of proteins. J. Chromatogr. 1984, 317, 141-155.
63. Geng, X., Ke, C., Chen, G., Liu, P. et al., On-line separation of native proteins by two-dimensional liquid chromatography using a single column. J. Chromatogr. A 2009, 1216, 3553-3562.
64. Mahn, A., Reyes, A., Zamorano, M., Cifuentes, W. et al., Depletion of highly abundant proteins in blood plasma by hydrophobic interaction chromatography for proteomic analysis. J. chromatogr. B Analyt. Technol. Biomed Life Sci. 2010, 878, 1038-1044.
65. Murphy, P. J., Stone, O. J., Anderson, M. E., Automated hydrophobic interaction chromatography column selection for use in protein purification. J. Vis. Exp. 2011, doi: 10.3791/3060.
66. Palani, S., Gueorguieva, L., Rinas, U., Seidel-Morgenstern, A. et al., Recombinant protein purification using gradient-assisted simulated moving bed hydrophobic interaction chromatography. Part I: selection of chromatographic system and estimation of adsorption isotherms. J. Chromatogr. A 2011, 1218, 6396-6401.
67. Mikolajczyk, S. D., Grauer, L. S., Millar, L. S., Hill, T. M. et al., A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 1997, 50, 710-714.
68. Sikanen, T., Aura, S., Franssila, S., Kotiaho, T., Microchip capillary electrophoresis-electrospray ionization-mass spectrometry of intact proteins using uncoated Ormocomp microchips. Anal. Chim. Acta. 2012, 711, 69-76.
69. Kim, K. H., Moon, M. H., Chip-type asymmetrical flow field-flow fractionation channel coupled with mass spectrometry for top-down protein identification. Anal. Chem. 2011, 83, 8652-8658.
70. Tran, J. C., Doucette, A. A., Multiplexed size separation of intact proteins in solution phase for mass spectrometry. Anal. Chem. 2009, 81, 6201-6209.
71. Taylor, G. K., Kim, Y. B., Forbes, A. J., Meng, F. et al., Web and database software for identification of intact proteins using "top down" mass spectrometry. Anal. Chem. 2003, 75, 4081-4086.
72. Durbin, K. R., Tran, J. C., Zamdborg, L., Sweet, S. M. et al., Intact mass detection, interpretation, and visualization to automate top-down proteomics on a large scale. Proteomics 2010, 10, 3589-3597.
73. Breuker, K., Jin, M., Han, X., Jiang, H. et al., Top-down identification and characterization of biomolecules by mass spectrometry. J. Am. Soc. Mass Spectrom. 2008, 19, 1045-1053.
74. Fagerquist, C. K., Sultan, O., Induction and identification of disulfide-intact and disulfide reduced β-subunit of Shiga toxin 2 from Escherichia coli O157:H7 using MALDI-TOF-TOF-MS/MS and top-down proteomics. Analyst 2011, 136, 1739-1746.
75. Poulsen, K., Bahl, J. M., Tanassi, J. T., Simonsen, A. H. et al., Characterization and stability of transhyretin isoforms in cerebrospinal fluid examined by immunoprecipitation and high-resolution mass spectrometry of intact protein. Methods 2012, 56, 284-292.
76. Michalski, A., Damoc, E., lange, O., Denisov, E. et al., Ultra high resolution linear ion trap Orbitrap mass spectrometer (Orbitrap Elite) facilitates top down LC MS/MS and versatile peptide fragmentation modes. Mol. Cell Proteomics 2012, 11, O111.013698.
77. TM 5600 System. 2011 AB SCIEX, publication number: 3240911-01, http://www.absciex.com/Documents/Downloads/Literature/4000-api-hardware-guide.pdf.
78. Lourette, N., Smallwood, H., Wu, S., Robinson, E. W. et al., A top-down LC-FTICR MS-based strategy for characterizing oxidized calmodulin in activated macrophages. J. Am. Soc. Mass Spectrom 2010, 21, 930-939.
79. Zhang, H., Cui, W., Wen, J. Blankenship, R. E. et al., Native electrospray and electron-capture dissociation in FTIR mass spectrometry provide top-down sequencing of a protein component in an intact protein assembly. J. Am. Soc. Mass Spectrom. 2010, 21, 1966-1968.
80. Kim, M., Pandey, A., Electron transfer dissociation mass spectrometry in proteomics. Proteomics 2012, 12, 530-542.
81. Lee, J. E., Kellie, J. F., Tran, J. C., Tipton, J. D. et al., A robust two-dimensional separation for top-down tandem mass spectrometry of the low mass proteome. J. Am. Soc. Mass Spectrom. 2009, 20, 2183-2191.
82. Ge, Y., Lawhorn, B. G., ElNaggar, M., Strauss, E. et al., Top down characterization of larger proteins (45 kDa) by electron capture dissociation mass spectrometry. J. Am. Chem. Soc. 2002, 124, 672-678.
83. Kellie, J. F., Catherman, A. D., Durbin, K. R., Tran, J. C. et al., Robust analysis of the yeast proteome under 50 kDa by molecular-mass-based fractionation and top-down mass spectrometry. Anal. Chem. 2012, 84, 209-215.
84. Tipton, J. D., Tran, J. C., Catherman, A. D., Ahlf, D. R. et al., Nano-LC FTICR tandem mass spectrometry for top-down proteomics: routine baseline unit mass resolution of whole cell lysate proteins up to 72 kDa. Anal. Chem. 2012, 84, 2111-2117.
85. Vellaichamy, A., Tran, J. C., Catherman, A. D., Lee, J. E. et al., Size-sorting combined with improved nanocapillary liquid chromatography-mass spectrometry for identification of intact proteins up to 80 kDa. Anal. Chem. 2010, 82, 1234-1244.
86. Han, X., Jin, M., Breuker, K., McLafferty, F.W., Extending top-down mass spectrometry to proteins with masses greater than 200 kilodaltons. Science 2006, 314, 109-112.
87. Lange, V., Picotti, P., Domon, B., Aebersold, R., Selected reaction monitoring for quantitative proteomics: a tutorial. Mol. Syst. Biol. 2008, 4, 222.
88. Kitteringham, N. R., Jenkins, R. E., Lane, C. S., Elliott, V. L. et al., Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics. J. Chromatogr. B Analyt. Technol. Biomed Life. Sci. 2009, 877, 1229-1239.
89. Malmstrom, L., Malstrom, J., Selevsek, N., Rosenberger, G., Automated workflow for large-scale selected reaction monitoring experiments. J. Proteome Res. 2012, 11, 1644-1653.
90. Sung, H. J., Jeon, S. A., Ahn, J. M., Seul, K. J. et al., Large-scale isotype-specific quantification of serum amyloid A 1/2 by multiple reaction monitoring in crude sera. J. Proteomics 2012, 75, 2170-2180.
91. Andrews, G. L., Simons, B. L., Young, J. B., Hawkridge, A. M., Performance characteristics of a new hybrid quadrupole time-of-flight tandem mass spectrometer (Triple TOF 5600). Anal. Chem. 2011, 83, 5442-5446.
92. Gillet, L. C., Navarro, P., Tate, S., Roest, H., Targeted data extraction of the MS/MS spectra generated by data independent acquisition: a new concept for consistent and accurate proteome analysis. Mol. Cell Proteomics 2012, 11, O111.016717.
93. Hopfgartner, G., Tonoli, D., Varesio, E., High-resolution mass spectrometry for integrated qualitative and quantitative analysis of pharmaceuticals in biological matrices. Anal. Bioanal. Chem. 2012, 402, 2587-2596.
94. Atamas, S. P., Alternative splice variants of cytokines: making a list. Life Sci. 1997, 61, 1105-1112.
95. Steinman, L., Nuanced roles of cytokines in three major human brain disorders. J. Clin. Invest. 2008, 118, 3557-3563.
96. Blair, C. A., Zi, X., Potential molecular targeting of splice variants for cancer treatment. Indian J. Exp. Biol. 2011, 49, 836-839.
97. Robinson, C. J., Stringer, S. E., The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J. Cell Sci. 2001, 114, 853-865.
98. Bates, D. O., Harper, S. J., Therapeutic potential of inhibitory VEGF splice variants. Future Oncol. 2005, 1, 467-473.
99. Hilmi, C., Guyot, M., Pages, G., VEGF spliced variants: possible role of anti-angiogenesis therapy. J. Nucleic Acids 2012, 2012, 162692.
100. Velloso, C. P., Harridge, S. D., Insulin-like growth factor-I E peptides: implications for aging skeletal muscle. Scand. J. Med. Sci. Sports 2010, 20, 20-27.
101. Boraschi, D., Lucchesi, D., Hainzl, S., Leitner, M. et al., IL-37: a new anti-inflammatory cytokine of the IL-1 family. Eur. Cytokine Netw. 2011, 22, 127-147.
102. White, E. S., Baralle, F. E., Muro, A. F., New insights into form and function of fibronectin splice variants. J. Pathol. 2008, 216, 1-14.
103. White, E. S., Muro, A. F., Fibronectin splice variants: understanding their multiple roles in health and disease using engineered mouse models. IUBMB Life 2011, 63, 538-546.
104. Marcucci, R., Romano, M., Thrombopoietin and its splicing variants: structure and functions in thrombopoiesis and beyond. Biochim. Biophys. Acta 2008, 1782, 427-432.
105. Dame, C., Wolber, E. M., Freitag, P., Hofmann, D. et al., Trombopoietin gene expression in the developing human central nervous system. Brain. Res. Dev. Brain Res. 2003, 143, 217-223.
106. Webb, K. E., Martin, J. F., Hamsten, A., Eriksson, P. et al., Polymorphisms in the thrombopoietin gene are associated with risk of myocardial infarction at a young age. Atherosclerosis 2001, 154, 703-711.
107. Hayes, N. V., Blackburn, E., Boyle, M. M., Russell, G. A. et al., Expression of neuregulin 4 splice variants in normal human tissues and prostate cancer and their effects on cell motility. Endocr. Relat. Cancer 2010, 18, 39-49.
108. Wu, J., Pungaliya, P., Kraynov, E., Bates, B., Identification and quantification of osteopontin splice variants in the plasma of lung cancer patients using immunoaffinity capture and targeted mass spectrometry. Biomarkers 2012, 17, 125-133.
109. Wei, J., Zaika, E., Zaika, A., p53 family: role of protein isoforms in human cancer. J. Nucleic Acids 2012, 2012, 687359.